脓毒症免疫治疗的研究进展:文献计量学分析
该文献计量学分析检索Web of Science核心合集2000年1月1日至2025年12月31日脓毒症免疫治疗相关论文,共纳入768篇文献,使用VOSviewer、CiteSpace等工具进行可视化分析。年发文量从2000—2015年平均11.3篇增至2021—2025年平均69.4篇,2024年达峰值79篇;美国以246篇、H指数55居首,中国174篇但引用影响力显著较低。关键词演变显示研究经历抗炎策略、免疫抑制与细胞水平研究、以及新冠疫情下免疫调节与整合管理等阶段,近年聚焦免疫检查点抑制剂与多组学整合。作者认为未来需跨国合作、加强转化研究并使用基于生物标志物的药物。
要点
- 脓毒症免疫治疗年发文量从2000—2015年平均11.3篇增至2021—2025年平均69.4篇,2024年峰值79篇。
- 美国发文246篇、H指数55居首;中国发文174篇但引用影响力显著较低。
- 关键词演变显示研究从靶向肿瘤坏死因子与细胞因子的抗炎策略,转向基于生物标志物的精准治疗。
- 近年研究领域包括免疫检查点抑制剂与多组学整合,提示向个体化算法发展。
- 作者认为国际合作缺乏协调拖慢研究进展,未来需跨国合作、加强转化研究并使用基于生物标志物的药物。
研究设计与关键结果
- 研究类型为文献计量学分析,纳入2000年1月1日至2025年12月31日Web of Science核心合集中脓毒症免疫治疗相关论文与综述共768篇。
- 年发文量从2000—2015年平均11.3篇/年增至2021—2025年平均69.4篇/年,2024年达峰值79篇。
- 美国发文246篇、H指数55居首;中国发文174篇但引用影响力显著较低。
- 美国为全球合作枢纽,与中国及欧洲国家联系紧密,欧洲各聚类间亦保持显著互联。
- 关键词演变分四阶段:2000—2005年聚焦靶向肿瘤坏死因子与细胞因子等关键介质的抗炎策略;2006—2012年转向认识临床复杂性与免疫抑制并扩展细胞水平研究;2013—2018年原文此处未描述;2019—2025年在新冠疫情背景下进入整合与应对新挑战阶段,以免疫调节、诊断与整合管理的多元临床进展为标志。
- Frontiers in Immunology发文最多(58篇);Singer等2016年Sepsis-3共识为被引最多的参考文献。
- 共被引分析显示Global Burden Study 2020与Rudd等的Sepsis-3共识分别为引用次数最多和共现强度最高的关键文献。
证据类型、等级与局限
- 证据类型:文献计量学分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis results in critical organ failure, considerable global mortality, and poses treatment obstacles. The primary issue with its pathophysiology is the improper functioning of the immune system in two phases: initially, there is excessive inflammation, followed by insufficient inflammation. This has generated interest in immunotherapy to restore the immune system to its normal state. This bibliometric analysis mapped the evolving research landscape of sepsis immunotherapy.
METHODS: Articles and reviews related to sepsis immunotherapy, published between January 1, 2000, and December 31, 2025, in the Web of Science Core Collection, were retrieved, and bibliometric visualization analysis was performed using tools such as VOSviewer, CiteSpace, Scimago Graphica, Charticulator, and the R package bibliometrix.
RESULTS: A bibliometric analysis of 768 papers (2000-2025) indicates that the domain of sepsis immunotherapy research is seeing rapid expansion and dynamism. The annual publication rate is increasing exponentially, from an average of 11.3 per year (2000-2015) to 69.4 per year (2021-2025), reaching a peak of 79 in 2024. The United States tops the list with 246 articles and an H-index of 55, while China ranks second with 174 publications but exhibits a significantly lower citation impact. The analysis of collaborative networks reveals that the United States serves as a global hub with strong connections to China and European nations, while the European clusters maintain significant interconnections as well. The evolution of keywords delineates four distinct research phases: 2000-2005: focus on anti-inflammatory strategies targeting pivotal mediators such as tumor necrosis factor and cytokines; 2006-2012: shift toward acknowledging clinical complexity and immunosuppression while broadening research at the cellular level; 2013-2018: 2019-2025: in the context of the coronavirus disease 2019 pandemic, a phase of integration and response to emerging challenges marked by diverse clinically oriented advancements in immunomodulation, diagnosis, and integrated management. Journals like Frontiers in Immunology published the most number of articles (58), while the 2016 Sepsis-3 Consensus by Singer et al. was the most cited reference, underscoring its considerable influence. Joint citation analysis revealed that the Global Burden Study 2020 and the Sepsis-3 Consensus by Rudd et al. were the pivotal publications with the highest citation counts and prevalence intensity, respectively, highlighting their significance as foundational sources of information.
CONCLUSIONS: This bibliometric analysis shows how quickly research on immunotherapy for sepsis is moving forward. It has gone from focusing on anti-inflammatory strategies to precision treatment methods based on biomarkers. The US is still the best at research results and influence, but the lack of coordination in international cooperation has made research move more slowly. Recent research domains, including immune checkpoint inhibitors and multiomics integration, suggest a progression towards personalized algorithms. To accomplish the best clinical results, the future focus must go beyond borders, strengthen translational research, and use drugs based on biomarkers.
参考来源
- Wang Z, Li X, Zhang J, et al. Research Progress of Sepsis Immunotherapy: A Bibliometric Analysis. Shock. 2026. PMID: 41770710. doi:10.1097/SHK.0000000000002826
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。